Carbonite Goes Public At $10 a Share, PeerTransfer Pulls In $7.5M, BuyWithMe Picks Up Scoop St., & More Boston-Area Deals News

8/17/11Follow @xconomy

This week’s New England deals list includes a mix of life sciences and IT companies.

—Lexington, MA-based T2 Biosystems, a developer of a system for identifying biological substances such as proteins, small molecules, viruses, and DNA more cheaply and quickly than existing methods, took in $23 million in Series D financing. New T2 investor Aisling Capital led the round, which also included return backers Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, Physic Ventures, Partners Healthcare, Arcus Ventures, RA Capital, Camros Capital, and WS Investments.

—Boston-based online data storage firm Carbonite raised $62.5 million in an initial public offering, selling 6.25 million shares at $10 per share. That was the bottom end of a range ($10 to $11) that Carbonite (NASDAQ: CARB) had already lowered earlier on the day it priced. Late last month it had said it expected to price the shares at $15 to $17 each.

—My colleague Greg wrote about how Harvard University’s Office of Technology Development is looking to raise another fund of $20 to $30 million, up from its $10 million “Accelerator Fund,” created to help the school’s scientists commercialize their inventions.

—Amesbury, MA-based Fluidnet, a maker of electronic infusion pumps for administering IV fluids, raised $19.8 million of an offering that could hit $25 million, according to an SEC filing.

—Proteon Therapeutics, a Waltham, MA-based kidney and vascular drug developer, nabbed $15.2 million from 19 investors, an SEC filing showed.

—Lexington-based Pulmatrix raised $14 million in Series B financing, to bring its total funding raised to $60 million. The investment came from all existing Pulmatrix investors, including Polaris Venture Partners, 5AM Ventures, Arch Venture Partners, and Novartis Venture Fund, and will go to advancing Pulmatrix’s lead compound, PUR118, as a new treatment for cystic fibrosis and chronic obstructive pulmonary disease (COPD).

—Embera NeuroTherapeutics, based in Sudbury, MA and Shreveport, LA, took in $4.5 million in Series A funding, to put toward EMB-001, its treatment for nicotine and cocaine addiction. The money came from existing Embera backers, Louisiana Ventures, Louisiana Fund I, and Themelios Ventures, as well as other private investors.

—PeerTransfer, a Boston-based provider of a platform for online college tuition payments for international students, picked up $7.5 million. The Series A financing was led by Spark Capital and also included Accel Partners, Maveron, and Boston Seed Capital. That all comes on top of the $1.1 million PeerTransfer raised in seed funding last October, from Spark, Project 11 Ventures, and other angel investors. The money will go to new hires and infrastructure as PeerTransfer grows to work with more schools.

—New York- and Boston-headquartered BuyWithMe acquired another startup in the group buying space, Scoop St., which is focused on New York City local deals. No financial terms were disclosed, but this makes for BuyWithMe’s fifth acquisition this year.

By posting a comment, you agree to our terms and conditions.